AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01985893 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib plus trastuzumab
Description: Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
Study NCT04384978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Serious Games with a Social Robot (Ryan)
Description: Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
Study NCT03029884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop DBS
Description: Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
Study NCT04641689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desk Only
Description: Provision of height-adjustable desk
Study NCT04641689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Desk Only
Description: Provision of height-adjustable desk
Study NCT04641689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Only
Description: Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
Study NCT04641689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program Only
Description: Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
Study NCT04662970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device programming
Description: Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
Study NCT02700633 — intervention group
Intervention type: DEVICE
Intervention: Pacemaker
Study NCT01887054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tower of Hanoi
Study NCT01887054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group - non use of Tower of Hanoi
Study NCT02299518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT02299518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV and PO
Study NCT02299518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02299518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO
Study NCT02299518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02299518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00886652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
Study NCT03317301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
Study NCT03317301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talion Tab
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Study NCT02910505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Laser for tattoo removal
Study NCT03377140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: 2 capsuls
Study NCT03377140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study NCT01873469 — intervention group
Intervention type: RADIATION
Intervention: Radiochemotherapy
Description: postoperative radiochemotherapy 60 Gy/ Temozolomide
Study NCT02518464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice per day
Description: Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
Study NCT01067924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
Study NCT01067924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing
Description: Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
Study NCT00265148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Extended Release Tablets
Study NCT00265148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo dummy to match
Study NCT02151773 — intervention group
Intervention type: DRUG
Intervention: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Study NCT00385476 — intervention group
Intervention type: BEHAVIORAL
Intervention: PMKT Questionnaire
Description: Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
Study NCT02597062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01929135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicated 2% atorvastatin dentifrice
Description: Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
Study NCT01929135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-medicated dentifrice
Description: Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
Study NCT00819793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CentriMag Ventricular Assist System
Description: All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
Study NCT02387476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRESCA mask first night
Description: FRESCA nasal mask first night
Study NCT03980314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03980314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02387476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Mask first night
Description: CPAP Nasal Mask first night
Study NCT00734747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medigus SRS endoscopic stapling system
Description: The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
Study NCT01730248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: 5 mg tablets administered orally twice daily
Study NCT01730248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: 10 mg and 50 mg hard gelatin capsules administered orally once daily
Study NCT03419858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
Study NCT03419858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Meditation
Description: A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
Study NCT03419858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-Breathing
Description: Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
Study NCT03419858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
Study NCT03419858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
Study NCT03419858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
Study NCT03419858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
Study NCT04384978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play Solitary Games Without a Social Robot
Description: Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
Study NCT01691508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
Study NCT01691508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Will be available as an equivalent volume of 0.9% sodium chloride.
Study NCT03135405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated messages
Description: Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
Study NCT03135405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home BP monitors
Description: Participants will have the option of receiving home blood pressure monitors.
Study NCT03135405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care partner reminders
Description: Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
Study NCT01691508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS (prednisone/prednisolone)
Description: Oral Corticosteroid (prednisone/prednisolone)
Study NCT01917838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG plus MyMFG
Description: Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process.
Study NCT05493930 — intervention group
Intervention type: OTHER
Intervention: The hospital where the treatment is performed
Study NCT02226952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, low dose
Study NCT02226952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, medium dose
Study NCT02226952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, high dose
Study NCT02226952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03027115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin treatment for 7 days pre-operatively
Study NCT02405325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
Study NCT02108925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: supplementary oxygen during exercise
Study NCT00004160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT04681703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led program on accuracy of blood pressure self-measurement
Description: The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
Study NCT01683032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: a capsule containing 20 mg
Study NCT00496457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 4 Capsules of PBO per day before noon meal
Study NCT04204980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab dose escalation
Description: - Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
Study NCT02426710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography
Description: Flutter ablation will be done using intracardiac echocardiography.
Study NCT02426710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracardiac echocardiography
Description: Flutter ablation will be done using intracardiac echocardiography.
Study NCT00004160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02666300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TaperGuard ETT
Description: tracheal intubation with TaperGuard ETT
Study NCT00527657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.
Study NCT00527657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m\^2 by mouth daily on Days 1 to 42.
Study NCT00527657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg/m\^2 by mouth daily.
Study NCT01933373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupet
Description: Laparoscopic posterior partial fundoplication plus myotomy.
Study NCT01933373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dor
Description: Anterior partial fundoplication plus myotomy.
Study NCT02713022 — intervention group
Intervention type: DEVICE
Intervention: DEXA Scan
Study NCT02713022 — intervention group
Intervention type: BEHAVIORAL
Intervention: Godin Leisure Time Exercise Questionnaire (GLTEQ)
Study NCT02817841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Study NCT00004160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT04204980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab full dose
Description: - Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
Study NCT01109862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Description: All cemented THA
Study NCT01109862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: Cemented bipolar HAP
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV
Description: Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ALVAC-HIV
Description: A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
Study NCT00004160 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AIDSVAX B/E
Description: Sodium Chloride for Injection, 0.9% administered IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for hepatitis B vaccine
Description: Sodium Chloride for Injection, 0.9% administered IM.
Study NCT02109354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tetanus vaccine
Description: Sodium Chloride for Injection, 0.9% administered IM.
Study NCT00783861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd Femina)